---
title: "IOL Chemicals & Pharmaceuticals Ltd (IOLCP) — Share Price, Financials & Analysis"
symbol: "IOLCP"
company: "IOL Chemicals & Pharmaceuticals Ltd"
canonical: "https://tapetide.com/stocks/IOLCP"
isin: "INE485C01029"
nse_symbol: "IOLCP"
bse_code: "524164"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 5943.93
generated_at: "2026-09-13T19:56:53.670Z"
---

# IOL Chemicals & Pharmaceuticals Ltd (IOLCP)

Canonical page: https://tapetide.com/stocks/IOLCP

## Company

- **NSE Symbol:** IOLCP
- **BSE Code:** 524164
- **ISIN:** INE485C01029
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2010-11-08
- **Face Value:** ₹2
- **F&O Eligible:** No
- **Website:** iolcp.com

## About

IOL Chemicals & Pharmaceuticals Ltd is a leading pharmaceutical (APIs) company and is a significant player in the specialty chemicals space. It serves the domestic and export market.[1]
It is the largest player of Ibuprofen (pain killer) globally with a world market share of 35%.[2]

## Latest Price

- **Price:** ₹194.31
- **Change:** -17.12 (-8.1%)
- **Open:** ₹210.51
- **Day High:** ₹210.95
- **Day Low:** ₹192
- **Previous Close:** ₹211.43
- **Volume:** 5129124
- **As Of:** 2026-09-11T10:29:12+00:00

## Key Fundamentals

Observed at 2026-09-11T04:45:04.090018Z.

- **Market Cap:** ₹5943.93 Cr
- **Classification:** Microcap
- **P/E (reported):** 36.9
- **P/E (TTM):** 33.91
- **EPS (TTM):** ₹5.73
- **EPS (reported):** ₹20.19
- **Book Value:** ₹61.27
- **Price to Book:** 3.45
- **Dividend Yield:** 0.47%
- **ROE:** 7.65%
- **ROCE:** 10.49%
- **Debt to Equity:** 0.08
- **Revenue (yearly):** ₹2340.4 Cr
- **Net Income:** ₹137.6 Cr
- **EBITDA:** ₹290.3 Cr
- **52-Week High:** ₹219.04
- **52-Week Low:** ₹67.19
- **RSI (14):** 74.69

## Tapetide Score

- **Score:** 64 / 100
- **Score date:** 2026-09-04
- **Archetype:** Cheap but Weak
- **What it means:** A low multiple sitting on weak financials. Worth establishing what the market is discounting before treating the low valuation as an opportunity — weak fundamentals often justify it.
- **Pillar profile:** Quality: Weak · Valuation: Cheap · Momentum: Rising
- **Percentile:** 95.6 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 60 | 9% |
| growth | 56.29 | 9% |
| momentum | 98.9 | 12% |
| ownership | 88.27 | 24% |
| quality | 47.96 | 22% |
| valuation | 66.65 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 22.1%
- Promoter holding has increased by 4.80% over last quarter.

### Weaknesses

- Stock is trading at 3.17 times its book value
- The company has delivered a poor sales growth of 3.35% over past five years.
- Company has a low return on equity of 7.74% over last 3 years.

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 19.99% | -26.04% | 130.33% |
| ebitda margin growth | 18.45% | 16.09% | 2.99% | -5.27% |
| net income growth | 21.05% | 36.1% | 2% | -20% |
| revenue growth | 23.03% | 11.36% | 2% | 3% |
| roce | 22.03% | 21.69% | -10.65% | 12.01% |
| roe | 21.14% | 27.71% | 7.33% | -36.46% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 545 | 520 | 504 | 502 | 526 | 523 | 528 | 552 | 568 | 580 | 619 | 756 |
| Expenses | 481 | 476 | 454 | 452 | 484 | 476 | 465 | 490 | 510 | 523 | 527 | 653 |
| Operating Profit | 64 | 44 | 50 | 51 | 42 | 47 | 63 | 62 | 57 | 57 | 93 | 104 |
| OPM % | 12 | 9 | 10 | 10 | 8 | 9 | 12 | 11 | 10 | 10 | 15 | 14 |
| Other Income | 7 | 8 | 8 | 7 | 6 | 4 | 5 | 7 | 7 | -6 | 2 | 8 |
| Interest | 4 | 4 | 3 | 2 | 4 | 4 | 4 | 4 | 3 | 4 | 3 | 4 |
| Depreciation | 16 | 16 | 16 | 17 | 18 | 19 | 19 | 20 | 20 | 20 | 20 | 21 |
| Profit before tax | 51 | 32 | 38 | 39 | 26 | 28 | 45 | 46 | 41 | 28 | 71 | 87 |
| Tax % | 26 | 28 | 25 | 24 | 26 | 26 | 30 | 25 | 26 | 25 | 25 | 26 |
| Net Profit | 38 | 23 | 28 | 30 | 19 | 21 | 32 | 34 | 30 | 21 | 53 | 64 |
| EPS in Rs | 1.29 | 0.79 | 0.96 | 1.01 | 0.65 | 0.7 | 1.08 | 1.16 | 1.02 | 0.7 | 1.81 | 2.2 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 983 | 1685 | 1894 | 1967 | 2184 | 2217 | 2133 | 2079 | 2319 | 2524 |
| Expenses | 863 | 1276 | 1321 | 1375 | 1927 | 1990 | 1901 | 1877 | 2049 | 2213 |
| Operating Profit | 120 | 410 | 574 | 592 | 257 | 227 | 232 | 202 | 270 | 310 |
| OPM % | 12 | 24 | 30 | 30 | 12 | 10 | 11 | 10 | 12 | 12 |
| Other Income | 6 | 10 | 16 | 24 | 17 | 25 | 30 | 22 | 9 | 11 |
| Interest | 64 | 51 | 21 | 6 | 8 | 16 | 16 | 15 | 15 | 14 |
| Depreciation | 30 | 32 | 36 | 39 | 43 | 46 | 63 | 72 | 80 | 82 |
| Profit before tax | 31 | 336 | 533 | 571 | 223 | 189 | 183 | 138 | 184 | 226 |
| Tax % | 12 | 30 | 32 | 22 | 26 | 26 | 26 | 27 | 25 | — |
| Net Profit | 28 | 237 | 361 | 445 | 166 | 140 | 135 | 101 | 138 | 168 |
| EPS in Rs | 0.99 | 8.32 | 12.7 | 15.15 | 5.64 | 4.77 | 4.61 | 3.44 | 4.69 | 5.73 |
| Dividend Payout % | 0 | 0 | 5 | 8 | 14 | 17 | 22 | 23 | 21 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 56 | 56 | 57 | 57 | 59 | 59 | 59 | 59 | 59 | 59 |
| Reserves | 132 | 160 | 417 | 757 | 1202 | 1332 | 1448 | 1553 | 1629 | 1740 |
| Borrowings | 447 | 422 | 284 | 59 | 3 | 44 | 80 | 33 | 117 | 135 |
| Other Liabilities | 182 | 214 | 184 | 297 | 347 | 526 | 434 | 600 | 577 | 653 |
| Total Liabilities | 817 | 852 | 942 | 1170 | 1610 | 1960 | 2021 | 2244 | 2382 | 2587 |
| Fixed Assets | 374 | 406 | 412 | 469 | 512 | 561 | 751 | 933 | 1170 | 1181 |
| CWIP | 21 | 7 | 27 | 19 | 48 | 105 | 90 | 101 | 22 | 96 |
| Investments | 0 | 0 | 0 | 0 | 1 | 2 | 20 | 21 | 21 | 21 |
| Other Assets | 422 | 439 | 503 | 682 | 1048 | 1292 | 1159 | 1190 | 1168 | 1289 |
| Total Assets | 817 | 852 | 942 | 1170 | 1610 | 1960 | 2021 | 2244 | 2382 | 2587 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 83 | 120 | 273 | 471 | 380 | 91 | 123 | 290 | 179 | 214 |
| Cash from Investing Activity | -23 | -50 | -63 | -184 | -317 | -121 | -119 | -191 | -154 | -198 |
| Cash from Financing Activity | -60 | -70 | -197 | -272 | -58 | -2 | -4 | -92 | 46 | -29 |
| Net Cash Flow | 1 | -1 | 13 | 15 | 4 | -31 | 0 | 7 | 70 | -13 |
| Free Cash Flow | 61 | 71 | 213 | 391 | 272 | -60 | -86 | 18 | -34 | 44 |
| CFO/OP | 82 | 105 | 83 | 102 | 88 | 60 | 75 | 144 | 97 | 93 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 58 | 54 | 43 | 52 | 56 | 79 | 83 | 81 | 90 | 95 |
| Inventory Days | 201 | 109 | 66 | 64 | 98 | 95 | 77 | 111 | 95 | 91 |
| Days Payable | 115 | 83 | 42 | 62 | 79 | 95 | 74 | 123 | 112 | 118 |
| Cash Conversion Cycle | 144 | 80 | 67 | 55 | 74 | 79 | 86 | 69 | 73 | 68 |
| Working Capital Days | 36 | 23 | 43 | 46 | 66 | 71 | 72 | 71 | 58 | 53 |
| ROCE % | 12 | 15 | 56 | 68 | 54 | 18 | 14 | 12 | 9 | 11 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 48.19% | 48.19% | 48.19% | 48.19% | 48.19% | 52.62% | 52.62% | 52.62% | 52.62% | 52.62% | 57.48% | 62.28% |
| FIIs | 2.34% | 2.18% | 1.41% | 1.39% | 1.63% | 1.49% | 1.47% | 2.59% | 2.25% | 2.08% | 1.72% | 4.87% |
| DIIs | 0.36% | 0.37% | 0.3% | 0.1% | 0.08% | 0.08% | 0.07% | 0.02% | 0.04% | 0.03% | 0.02% | 0.43% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 30.28% | 30.63% | 30.98% | 31.48% | 31.31% | 31.23% | 31.43% | 30.22% | 29.97% | 30.51% | 31.03% | 26.95% |
| Others | 18.84% | 18.62% | 19.12% | 18.84% | 18.79% | 14.58% | 14.4% | 14.54% | 15.12% | 14.76% | 9.74% | 5.47% |
| No. of Shareholders | 135397 | 134235 | 130003 | 128689 | 125979 | 126701 | 130002 | 125040 | 136129 | 133531 | 131550 | 119311 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 12 / 5 / 2

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 200.8 | Sell |
| EMA (10) | 199.65 | Sell |
| SMA (20) | 186.71 | Buy |
| EMA (20) | 190.19 | Buy |
| SMA (50) | 169.55 | Buy |
| EMA (50) | 170.94 | Buy |
| SMA (100) | 144.48 | Buy |
| EMA (100) | 149.63 | Buy |
| SMA (200) | 111.42 | Buy |
| EMA (200) | 126.31 | Buy |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 57.08 | Neutral |
| MACD (12,26,9) | 12.18 | Buy |
| Stochastic (14,3,3) | 73.35 | Neutral |
| ADX (14) | 39.97 | Buy |
| Williams %R (14) | -48.1 | Neutral |
| ATR (14) | 10.75 | High Volatility |
| ROC (12) | 4.46 | Buy |
| Stoch RSI (14) | 0 | Buy |
| UO (7,14,28) | 45.92 | Neutral |

## Analyst Ratings

| Recommendation | Analysts | Share |
| --- | --- | --- |
| Buy | 1 | 100% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |

Based on 1 analyst ratings, observed at 2026-09-11T04:45:04.025899+00:00.

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 9 Apr - IOLCP joined IEPFA’s Saksham Niveshak campaign; shareholders to update KYC and claim unpaid dividends by 9 July 2026. | [Disclosure Under Regulation 30 - Participation In 'Saksham Niveshak' Campaign 9 Apr - IOLCP joined IEPFA’s Saksham Niveshak campaign; shareholders to update KYC and claim unpaid dividends by 9 July 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7f610ba3-2d96-43dc-9d32-bb74845d5a90.pdf) |
| 6 Mar - EDQM granted CEP for Metformin Hydrochloride Process-II on 5 March 2026, adding to existing CEP. | [EDQM Issued CEP Certificate For 'METFORMIN HYDROCHLORIDE Process-II' 6 Mar - EDQM granted CEP for Metformin Hydrochloride Process-II on 5 March 2026, adding to existing CEP.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/17acf643-a504-48ca-9cf7-a793070fcd5b.pdf) |
| 2d - Customs authority confirmed Rs 2.06 crore demand, penalty and fine; company will appeal. | [Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 2d - Customs authority confirmed Rs 2.06 crore demand, penalty and fine; company will appeal.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/4b232235-8a1a-447d-b13e-d3a8ff043821.pdf) |
| 24 Feb - EDQM issued CEP for Clopidogrel Besilate on 23 Feb 2026; adds to existing Clopidogrel Bisulphate CEP. | [EDQM Issued CEP Certificate For 'CLOPIDOGREL BESILATE' 24 Feb - EDQM issued CEP for Clopidogrel Besilate on 23 Feb 2026; adds to existing Clopidogrel Bisulphate CEP.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/540754f1-f532-4039-a618-af5c968522b4.pdf) |
| 20 Mar - NCVI Enterprises bought 4,04,305 shares on 19/03/2026; promoter stake rose to 16.58% (4,86,55,000). | [Disclosure Under SEBI (Prohibition Of Insider Trading Regulation), 2015 20 Mar - NCVI Enterprises bought 4,04,305 shares on 19/03/2026; promoter stake rose to 16.58% (4,86,55,000).](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1195045d-b598-43fe-8acb-961859a021ce.pdf) |
| 2 Mar - Ethyl Acetate 100k→120k MTPA; Acetic Anhydride 25k→32k MTPA. Capex Rs4cr and Rs5.71cr; completed 2 Mar 2026. | [Disclosure Pursuant To Regulation 30 Of The SEBI (LODR) Regulations, 2015 2 Mar - Ethyl Acetate 100k→120k MTPA; Acetic Anhydride 25k→32k MTPA. Capex Rs4cr and Rs5.71cr; completed 2 Mar 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b6e9d370-8485-43c0-a08a-304170998922.pdf) |
| 19 Mar - NCVI Enterprises acquired 7,00,000 shares on-market on 18/03/2026; stake ~16.44%. | [Disclosure Under SEBI (Prohibition Of Insider Trading Regulation), 2015 19 Mar - NCVI Enterprises acquired 7,00,000 shares on-market on 18/03/2026; stake ~16.44%.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1655b7ce-8ccc-403d-ba1f-ed8762295528.pdf) |
| 19 Mar - NCVI acquired 700,000 IOLCP shares (0.24%) on 18 Mar 2026; stake 57.34%. | [Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 19 Mar - NCVI acquired 700,000 IOLCP shares (0.24%) on 18 Mar 2026; stake 57.34%.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4A943FE6_0DFB_443A_AA17_2947F3FA66DA_154555.pdf) |
| 12h - Purchased 6,54,123 IOL Chem shares on 17 Mar 2026; stake increased to 57.08%. | [Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 12h - Purchased 6,54,123 IOL Chem shares on 17 Mar 2026; stake increased to 57.08%.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/ECA64B19_1B59_4BEF_A102_CA0A067D6878_151814.pdf) |
| 12h - NCVI Enterprises bought 700,000 IOLCP shares on-market on 16-Mar-2026; stake rises to ~16.20%. | [Disclosure Under SEBI (Prohibition Of Insider Trading Regulation), 2015 12h - NCVI Enterprises bought 700,000 IOLCP shares on-market on 16-Mar-2026; stake rises to ~16.20%.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/98c581a6-551c-45b1-b29d-613496453b88.pdf) |

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-10 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bc6696e9-d768-4a86-8b6c-692baccbc412.pdf) |
| 2026-09-09 | [Expansion Of Ibuprofen Capacity New CDMO Business For Pharmaceutical Formulations And Dedicated Specialty Chemicals Manufacturing Facility](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8be05fe4-0ab2-455e-abfc-4edf36c3ed58.pdf) |
| 2026-09-02 | [Shareholder Meeting / Postal Ballot-Outcome of AGM](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2cf6deaa-18af-4c6f-98a8-3710418f9ee8.pdf) |
| 2026-09-02 | [Shareholder Meeting / Postal Ballot-Scrutinizers Report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=590a090f-c118-4506-acb9-4931ab1fb7d4.pdf) |
| 2026-08-26 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6870b63e-3efc-4f8b-a3cd-2044790a9297.pdf) |
| 2026-08-18 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a25053d1-dd48-410f-b27a-d74828febf69.pdf) |
| 2026-08-11 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4bd0a602-4111-4802-b2a9-663763dcfb6d.pdf) |
| 2026-08-11 | [Communication To The Shareholders Regarding AGM Notice And Annual Report For The Financial Year 2025-26](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=52166e3e-948c-43c3-92ec-b5621ed8671b.pdf) |
| 2026-08-10 | [Board Meeting Outcome for Outcome Of The Board Meeting And Submission Of Unaudited Financial Results Of The Company For The Quarter Ended 30Th June 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0c753eab-aaff-421b-a593-986ddea1c725.pdf) |
| 2026-08-10 | [Announcement under Regulation 30 (LODR)-Press Release / Media Release](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=44234e21-68d7-4f05-9bb6-7428fa19badb.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2026-08-20 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0e84e303-d463-4a3c-8566-e518e3065d25.pdf) |
| 2026-05-28 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=00eb6992-89f3-4cfe-9ec9-a618ad1530d3.pdf) |
| 2026-02-18 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a671a6a6-9958-40ea-815a-d07b5e19183a.pdf) |
| 2025-11-19 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=94dc8ddb-b216-4d23-a04c-7778ad2f7951.pdf) |
| 2025-08-13 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=be32446f-df9d-4cd7-9e01-f5c8ae5457e7.pdf) |
| 2025-05-27 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=882c5ebc-c90d-4d32-8c26-c8fb487750d1.pdf) |
| 2025-02-18 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=41a08411-de16-44b4-9bbd-4312ed31c978.pdf) |
| 2024-11-26 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e89694a5-3b06-45b8-b3dd-9b51bd52884d.pdf) |
| 2024-08-20 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=98ca443d-a0fa-4939-98f9-3aede430d721.pdf) |
| 2024-05-21 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d97f031c-fe8d-4906-baba-bfb7ebb45612.pdf) |

### Earnings Call Recordings

| Date | Document |
| --- | --- |
| 2026-08-13 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fa9a8156-be22-4861-a9e2-8fb1efd0eabd.pdf) |
| 2026-05-22 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5cc1ca3e-f571-49b1-b207-716f0dfe2b96.pdf) |
| 2026-02-12 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f4a06638-c881-49e1-88ce-e7de62e608d4.pdf) |
| 2025-11-13 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=81eb8c14-c7f3-4fb7-9935-485436404cb7.pdf) |
| 2025-08-08 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7cd0111d-6d17-47e8-9f79-7335f9ef2d09.pdf) |
| 2025-05-20 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bd23a6b9-f149-4961-8a5a-f0cdfcbb646c.pdf) |
| 2024-11-19 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b1461270-00da-47d9-81c3-82e589d39551.pdf) |
| 2024-08-13 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d320209f-85d3-41c6-b646-bfa92d72fe82.pdf) |
| 2024-05-16 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d1ba900d-1182-4e72-89c2-ed990b947791.pdf) |
| 2024-02-08 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=168f61ea-257a-4561-8cb8-a952b0619458.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-08-12 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=aad7ef47-c15e-442e-9055-c4d770a40f07.pdf) |
| 2026-05-21 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=789beb1c-309c-4961-8c64-12117069d62b.pdf) |
| 2026-02-12 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=763318ae-b6f3-4301-81b5-28ce5ceebbae.pdf) |
| 2025-11-12 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=94b73f8b-4b36-46c7-bfcd-bf049d2e084a.pdf) |
| 2025-08-07 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=da87a96a-d114-4778-8717-fcddd91e873a.pdf) |
| 2025-05-19 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=278b0efc-94ac-408c-808e-fb328bc7b857.pdf) |
| 2025-02-13 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f6ed3a16-daa9-4976-a8f3-33c3ee2b5a90.pdf) |
| 2024-11-18 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0577f9c7-a51f-4d5c-98fd-b88d31b82e7f.pdf) |
| 2024-08-12 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9d4e0ee6-7380-4d5f-a8ae-028a6c3e9d7c.pdf) |
| 2024-05-15 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=401a1c0a-205b-4650-8637-4f912e231bb2.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-10 | [Outcome Of The Board Meeting And Submission Of Unaudited Financial Results Of The Company For The Quarter Ended 30Th June 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7ee0719c-6720-44fd-9ef3-8b0de9efd604.pdf) |
| 2026-05-20 | [Outcome Of The Board Meeting And Submission Of Audited Financial Results For The Quarter And Year Ended 31St March 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1b1f088d-ee43-48e1-94f5-fe0f49aa84b1.pdf) |
| 2026-02-11 | [Un-Audited Financial Results For The Quarter And Nine Months Ended 31St December 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4ca83733-485b-44f5-a103-7b49060f19ae.pdf) |
| 2025-11-11 | [Un-Audited Financial Results For The Quarter And Half Year Ended 30Th September 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ddfc9683-6dd5-46bd-a1d7-b156b4175656.pdf) |
| 2025-08-07 | [Un-Audited Financial Results For The Quarter Ended 30Th June 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e7a91e1d-ada8-4879-8de9-d48084006cdb.pdf) |
| 2025-05-16 | [Audited Financial Results For The Quarter And Year Ended 31St March 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f3b62009-dba0-4ff6-80c8-16ee4994867e.pdf) |
| 2025-02-12 | [Un-Audited Financial Results For The Quarter And Nine Months Ended 31St December 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=eb8b40de-da84-473d-b519-ce94cba3a9ad.pdf) |
| 2024-11-14 | [Un-Audited Financial Results For The Quarter And Half Year Ended 30Th September 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=12439bfd-cbdf-4361-80e0-c79658f42c1d.pdf) |
| 2024-08-09 | [Un-Audited Financial Results For The Quarter Ended 30Th June 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7da5ca30-8d69-4623-877b-cd2c5935f7c1.pdf) |
| 2024-05-14 | [Outcome Of The Board Meeting Dated 14Th May 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=402e2a9a-babd-495d-9d6b-1720b9a9da8f.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/94dc8ddb-b216-4d23-a04c-7778ad2f7951.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e89694a5-3b06-45b8-b3dd-9b51bd52884d.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/19fb3bea-9b8c-4f80-9ac2-5f737bfff43b.pdf) |
| Nov 2022 | [Concall - Nov 2022](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9c360dc0-5af7-471e-a222-3bb690fd9211.pdf) |
| Nov 2022 | [Concall - Nov 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9c360dc0-5af7-471e-a222-3bb690fd9211.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/00eb6992-89f3-4cfe-9ec9-a618ad1530d3.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/00eb6992-89f3-4cfe-9ec9-a618ad1530d3.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/789beb1c-309c-4961-8c64-12117069d62b.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/789beb1c-309c-4961-8c64-12117069d62b.pdf) |
| May 2025 | [Concall - May 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/882c5ebc-c90d-4d32-8c26-c8fb487750d1.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2026 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5aadd5a2-8771-4549-8927-fed4d1523fe9.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/cc0de24d-5d21-46ac-91f5-840c4877eba2.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/214ffd8b-127d-4a4b-b7e9-4742b1996d1d.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/754e3c9b-64fa-4430-b0b1-f7817ed50c28.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:56:53.670Z.